Indonesia has become one of the most attractive markets for investors during 2014-2015. Implementation of the Jaminan Kesehatan Nasional (JKN) scheme, initiated in January 2014, has been one of the major drivers besides the initiatives by the new government elected in 2014. As per the initial reports, patient volumes have significantly increased after the implementation of the scheme. (A few clinics in Bandung reported up to a 200% rise in patient volumes in the first 2 months after the scheme’s implementation). The market anticipates a high requirement of hospital beds, medical devices, affordable and low-cost medicines, and diagnostic services to meet the growing demand. This study explores the broad competitive landscape and regulatory environment, which can be considered by investors while entering the Indonesian healthcare market in 2015 and beyond.